NCT00799643已完成2 期
Targeting Inflammation in Type 2 Diabetes: Clinical Trial Using Salsalate
适应症
干预措施
相关药物
试验速览
- 阶段
- 2 期
- 状态
- 已完成
- 入组人数
- 638
- 试验地点
- 21
- 主要终点
- The Primary Outcome for the TINSAL-T2D Study is Change in HbA1c Level From Baseline to Week 48 From Baseline, Compared Between Treatment Groups.
研究概览
简要总结
Growing evidence over recent years supports a potential role for low grade chronic inflammation in the pathogenesis of insulin resistance and type 2 diabetes. In this study we will determine whether salsalate, a member of the commonly used Non-Steroidal Anti-Inflammatory Drug (NSAID) class, is effective in lowering sugars in patients with type 2 diabetes. The study will determine whether salicylates represent a new pharmacological option for diabetes management. The study is conducted in two stages. Enrollment in the first stage is complete. The primary objective of the first stage was to select a dose of salsalate that is both well-tolerated and demonstrates a trend toward improvement in glycemic control. The primary objective of Stage 2 of the study is to evaluate the effects of salsalate on blood sugar control in diabetes; the tolerability of salsalate use in patients with type 2 diabetes (T2D); and the effects of salsalate on measures of inflammation, the metabolic syndrome, and cardiac risk.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
入排标准
- 年龄范围
- 18 Years 至 75 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Type 2 diabetes on diet and exercise therapy or monotherapy with metformin, insulin secretagogue (including SFU, non-SFU, and dipeptidyl peptidase IV (DPP-4) inhibitors), alpha-glucosidase inhibitors, or bile acid sequestrants (dosed once per day such that study drug can be administered ≥ 4 hours prior to sequestrant); or a combination of up to two of these at maximal dose. Dosing must be stable for 8 weeks prior to screening. Participant must have been diagnosed with T2D at least 8 weeks before screening.
- •FPG ≤ 225 mg/dL and HbA1c≥7% and ≤ 9.5% at screening.
- •Age ≥18 and <75
- •Women of childbearing potential agree to use an appropriate contraceptive method (hormonal, IUD, or diaphragm)
排除标准
- •No prior participation in Stage I of TINSAL-T2D ; exception: a participant who failed screening for HbA1c in Stage I will be allowed to re-screen for Stage II.
- •Type 1 diabetes and/or history of ketoacidosis determined by medical history
- •History of severe diabetic neuropathy including autonomic neuropathy, gastroparesis or lower limb ulceration or amputation
- •History of long-term therapy with insulin (>30 days) within the last year
- •Therapy with rosiglitazone (Avandia) or pioglitazone (Actos), alone or in combination in the previous 6 months; or exendin-4 (Byetta), alone or in combination in the previous 3 months
- •Pregnancy or lactation
- •Patients requiring oral corticosteroids within 3 months or recurrent continuous oral corticosteroid treatment (more than 2 weeks)
- •Use of weight loss drugs [e.g., Xenical (orlistat), Meridia (sibutramine), Acutrim (phenylpropanol-amine), or similar over-the-counter medications] within 3 months of screening or intentional weight loss of ≥ 10 lbs in the previous 6 months
- •Surgery within 30 days prior to screening
- •Serum creatinine >1.4 for women and >1.5 for men or eGFR <60 [possible chronic kidney disease stage 3 or greater calculated using the Modification of Diet in Renal Disease (MDRD) equation
- •History of chronic liver disease including hepatitis B or C
- •History of peptic ulcer or endoscopy demonstrated gastritis
- •History of acquired immune deficiency syndrome or human immunodeficiency virus (HIV)
- •History of malignancy, except participants who have been disease-free for greater than 10 years, or whose only malignancy has been basal or squamous cell skin carcinoma
- •New York Heart Association Class III or IV cardiac status or hospitalization for congestive heart failure
- •History of unstable angina, myocardial infarction, cerebrovascular accident, transient ischemic attack or any revascularization within 6 months
- •Uncontrolled hypertension (defined as systolic blood pressure >150 mmHg or diastolic blood pressure >95 mmHg on three or more assessments on more than one day). If on blood pressure medications, dosing should be stable for 2 weeks prior to randomization.
- •History of drug or alcohol abuse, or current weekly alcohol consumption >10 units/week (1 unit = 1 beer, 1 glass of wine, 1 mixed DCCktail containing 1 ounce of alcohol)
- •Hemoglobin <12 g/dL (males), <10 g/dL (females) at screening*
- •Platelets <100,000 cu mm at screening
- •AST (SGOT) >2.50 x ULN or ALT (SGPT) >2.50 x ULN at screening
- •Total Bilirubin >1.50 x ULN at screening
- •Triglycerides (TG) >500 mg/dL at screening
- •Poor mental function or any other reason to expect patient difficulty in complying with the requirements of the study
- •Previous allergy to aspirin
- •Chronic or continuous use (daily for more than 7 days) of nonsteroidal anti-inflammatory drugs within the preceding 2 months
- •Use of warfarin (Coumadin), clopidogrel (Plavix), dipyridamole (Persantine), heparin or other anticoagulants
- •Use of probenecid (Benemid, probalan), sulfinpyrazone (Anturane) or other uricosuric agents
- •Macroalbuminuria, defined as spot urine protein >300 mcg/mg Cr at screening
- •Pre-existing chronic tinnitus
研究组 & 干预措施
1
Active Comparator
Salsalate, 3.5 g/d orally, divided dosing
干预措施: Salsalate (Drug)
2
Placebo Comparator
Salsalate Placebo, orally, divided dosing
干预措施: Salsalate Placebo (Drug)
结局指标
主要结局
The Primary Outcome for the TINSAL-T2D Study is Change in HbA1c Level From Baseline to Week 48 From Baseline, Compared Between Treatment Groups.
时间窗: 48 weeks from baseline
HbA1c (%, percentage of HbA1c) change from baseline.
次要结局
- Changes in WBC and Differential, High-sensitivity C Reactive Protein (hsCRP), Other Inflammatory Markers(24 and 48 weeks)
- Response Rates for Reduction in Fasting Glucose of ≥20 mg/dl, a Reduction in HbA1c of ≥0.5%, and a Reduction in HbA1c of ≥0.8%(24 and 48 weeks)
- Change From Baseline in Fasting Glucose Over Time.(48 weeks from baseline)
- Response Rates for Exceeding Hyperglycemic Targets Between Active and Placebo Treated Groups; Need for Rescue Therapy; Need for Discontinuation of Study Medication(24 and 48 weeks)
- Response Rates in Patients Initially Treated With Lifestyle Modification, Insulin Secretagogue, Metformin or Combination Therapy(24 and 48 weeks)
- Change in Lipids (Low-density Lipoprotein Cholesterol [LDL-C], Non-high-density Lipoprotein Cholesterol [Non-HDL-C], Triglycerides [TG], Total Cholesterol [TC], High-density Lipoprotein Cholesterol [HDL C], TC/HDL-C Ratio, and LDL-C/HDL-C Ratio)(48 weeks)
研究者
研究点 (21)
Loading locations...
相似试验
已完成
2 期
Targeting INflammation Using SALsalate in Type 2 Diabetes (TINSAL-T2D)Type 2 DiabetesNCT00392678Joslin Diabetes Center277
Unknown
4 期
Type 2 Diabetes Mellitus and AtherosclerosisType 2 Diabetes MellitusNCT01250340University of Roma La Sapienza80
已完成
不适用
Type 2 Diabetes Mellitus as Catalyst for Alzheimer's DiseaseAlzheimer´s DiseaseDiabetes Mellitus Type 2NCT02501876Hospital Universitari Vall d'Hebron Research Institute202
已完成
不适用
Effect of Dietary Inflammatory Index on Inflammatory Markers and Metabolic Parameters, in Patients With Type 2 Diabetes MellitusDietary Inflammatory Index (DII)InflammationMedical Nutrition TherapyType 2 DiabetesNCT05271695Istanbul University150
Unknown
4 期
Anti-inflammatory Status in DM2 Treated PatientsDiabetes Mellitus, Type 2NCT04392557University of Catanzaro36